- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Episode 2 of "Not So Different: a Podcast From the Center for Biosimilars"
In this episode of Not So Different, you’ll hear providers and patient advocates on the issue of nonmedical switching among brand-name biologics and biosimilars in rheumatology and oncology indications.
In our first episode, we brought you a discussion of biosimilar interchangeability from experts across the biosimilars landscape. Interchangeable biosimilars haven’t yet become a reality in the US marketplace, and, as of yet, there is no pharmacy-level substitution of interchangeable biosimilars for brand-name products.
However, patients and their providers may still face a change of biologic therapies when payers institute a nonmedical switch.
In today’s episode of Not So Different, you’ll hear providers and patient advocates on the issue of nonmedical switching among brand-name biologics and biosimilars in rheumatology and oncology indications.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Biosimilars Policy Roundup for March 2023—Podcast Edition
April 2nd 2023On this episode of Not So Different, we discuss some of the global biosimilar policy news that came out during the month of March, including a new bill in Congress and 2 Canadian jurisdictions implementing switching policies.
Biosimilars Gastroenterology Roundup for February 2023—Podcast Edition
March 5th 2023On this episode of Not So Different, we chronicle the latest gastroenterology news from February, including several updates on adalimumab and infliximab biosimilars and industry analyses on the utilization of these drugs and patient confidence in gastroenterologists’ recommendations.
